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The variation and phylogenetic relationship of open reading frame 5 (ORF5) of 3 different laboratory strains of the original
prototype Bucyrus strain of equine arteritis virus (EAV), the modified live virus vaccine (ARVAC, Fort Dodge Laboratories),
and 18 field isolates of EAV from North America and Europe were determined by comparison of their gene sequences. The
viruses differed from the published sequence by between 3 (99.6% homology) and 94 (87.8%) nucleotides and by between
3 (98.8%) and 24 (90.6%) amino acids. The field isolates differed from each other by between 2 (99.7%) and 110 (85.7%)
nucleotides and by between 1 (99.6%) and 26 (89.8%) amino acids. Comparison of the nucleotide sequences of these viruses
indicates that although they are very closely related, the ORF5 of each virus is distinct. The ORF5 of EAV encodes the GL
envelope glycoprotein which expresses the neutralization determinants of the virus. Comparative analysis of the deduced
amino acid sequence of the GL protein of the viruses identified three distinct variable regions (V1 [aa 61–121], V2 [141–
178], and V3 [aa 202–222]), a putative signal sequence (S [aa 1–18]), and four conserved regions (C1 [aa 19–60], C2 [aa
122–140], C3 [aa 179–201], and C4 [aa 223–255]). Amino acid substitutions in the V1 region of the GL protein of EAV field
isolates had significant effects on the predicted hydrophobicity and secondary structure of the protein, which is potentially
important because this region contains a major neutralization site. Estimation of genetic distances and phylogenetic tree
analysis of these viruses identified four distinct groups of EAV isolates, including two North American (NA1 and NA2) and
two European (E1 and E2) groups. The sequence data obtained from individual European and North American isolates
suggest movement of viruses between the two continents. q 1995 Academic Press, Inc.
Equine arteritis virus (EAV), the causative agent of (GS) and 29-kDa (GL) envelope glycoproteins, ORF6 en-
codes a 17-kDa unglycosylated envelope protein (M),equine viral arteritis, is a small enveloped positive-
stranded RNA virus that was first isolated in 1953 (1). It and ORF7 encodes the phosphorylated 14-kDa nucleo-
capsid protein (N). The GL envelope glycoprotein en-recently has been established that EAV, simian hemor-
coded by ORF5 expresses the neutralization determi-rhagic fever virus, lactate dehydrogenase-elevating virus
nants of EAV (6–10).(LDV), and porcine reproductive and respiratory syn-
RNA viruses are often genetically heterogeneous, anddrome virus share sufficient characteristics to be in-
a particular genome with variable numbers of mutationscluded in a new family, the Arteriviridae (2, 3).
may be selected over others altering the phenotype ofThe EAV genome consists of approximately 12,687 nu-
the virus (11–14). Although there is only one serotype ofcleotides with a poly(A) tail at the 3* end (4). The genome
EAV, genetic variation among field strains of the virusincludes eight open reading frames (ORFs; 1a, 1b, 2, 3,
has been demonstrated by RNase T1 oligonucleotide4, 5, 6, and 7). ORFs 1a and 1b encode the viral replicase
fingerprinting (15, 16). Nucleotide sequence homologiesand ORFs 2, 5, 6, and 7 encode known structural viral
and phylogenetic tree analysis of M and N protein genesproteins (5). ORFs 2 and 5 respectively encode 25-kDa
of 10 EAV isolates demonstrated strain variation and pos-
sible RNA recombination between EAV isolates (17). Su-
The nucleotide sequence data reported in this article have been
gita et al. showed the existence of distinct geographicdeposited with the GenBank Database under Accession Nos. U38479
groupings of EAV isolates by sequence analysis of the(ARVAC), U38591 (ATCC), U38592 (AUT68), U38593 (AZ87), U38594
(CAN86), U38595 (EAVCVDLS), U38596 (IL93AB), U38597 (IL93TB), M protein gene of viruses from Europe and the United
U38598 (ITA92), U38599 (KY63), U38600 (KY77), U38601 (KY84), U38602 States (18). Data are not yet available, however, for ORF5
(KY93), U38603 (MI93), U38604 (MT89), U38605 (NE88), U38606 (NE89), which encodes the GL protein, the protein that expressesU38607 (PA76), U38608 (PLD76), U38609 (SWZ64), U38610 (EAVUCD),
the neutralization determinants of EAV (6–10). Nucleo-and U38611 (VBS53).
tide heterogeneity in ORF5 would be expected to lead to1 To whom correspondence and reprint requests should be ad-
dressed. antigenic variation of the GL protein of EAV and perhaps
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changes in the neutralization determinants of EAV, al- for amplification and sequencing of the ORF5 and flank-
ing portions of ORF4 and ORF6 from each virus, as pre-though cross-neutralization studies with polyclonal anti-
sera and a small panel of monoclonal antibodies have viously described (7; positive primers: 11023–11042,
11085–11106, 11255–11276, 11490–11511, 11540–failed to demonstrate significant antigenic variation be-
tween EAV isolates (10, 19–21). In contrast, preliminary 11561, and 11590–11611; negative primers: 11940–
11961, 11978–11998, 11674–11695, 11623–11642,phenotypic characterization of EAV field isolates using
an extensive panel of neutralizing monoclonal antibodies 11425–11445, and 11218–11239). The negative primer
11978–11998 was used to reverse transcribe the posi-has shown some antigenic variation in the GL protein
(U. B. R. Balasuriya et al., in preparation). tive-sense viral RNA to cDNA. Most of the viruses were
amplified with primers 11978–11998 and 11023–11042,The primary goal of this study was to characterize
the genetic variation and evolutionary relationships of 3 whereas primers 11978–11998 and 11085–11106 were
used to amplify this region from AZ87, MT89, and NE89.different laboratory strains of the original prototype Bu-
cyrus isolate of EAV, the modified live virus vaccine (AR- Both positive and negative strands of the cDNA from
each amplicon were sequenced with at least three prim-VAC), and 18 field isolates of EAV from North America
and Europe, by comparison of their ORF5 gene se- ers per strand by PCR-based cycle sequencing using
the ‘‘fmol’’ sequencing kit (Promega, WI). Phylogeneticquences as determined by reverse transcriptase–poly-
merase chain reaction sequencing. Second, we wished analysis was done with the DNADIST and FITCH pro-
grams of the PHYLIP (Phylogeny Inference Package) Ver-to identify the conserved and divergent regions in the GL
envelope glycoprotein of different field isolates of EAV. sion 3.5c for Macintosh Power PC (27) and ORF5 of LDV
was used as an outgroup to generate a routed tree (28,The North American viruses were isolated from the cen-
tral and eastern (Kentucky, Nebraska, Michigan, Illinois, 29). The ORF5 of LDV encodes the VP3 membrane glyco-
protein, which is the counterpart of the GL protein of EAVOhio, and Pennsylvania) and western (Arizona, Montana)
United States and western Canada (Alberta). The Euro- (28). The regions of ORF4 and ORF6 flanking ORF5 were
not included in the phylogenetic analysis. Bootstrap sam-pean viruses were isolated from Switzerland, Poland,
Austria, and Italy. The geographical location, year of iso- pling (30) was carried out on 1000 replicate datasets to
assess the confidence limits of the branch pattern. Alation, horse breed of origin, and passage history of the
EAV isolates used in this study are listed in Table 1. All value 90% was considered significant.
The ORF5 sequences of all 18 EAV field isolates, thefield isolates had been passaged in cell cultures, with
the exception of a virulent Bucyrus strain (VBS53) that ARVAC vaccine, and 3 laboratory strains were compared
to the published sequence of EAVUtr (4). The ORF5 ofhad been passaged only in horses and harvested as
pleural fluid. It is appreciated that adaptation of viruses all 18 EAV field isolates, the ARVAC vaccine, and the
ATCC laboratory strain was 768 nucleotides in length.to cell culture might itself result in genetic selection.
The commercial modified live attenuated vaccine virus The sequence of ORF5 of the EAVUCD and EAVCVDLS
(parent virus of EAVUCD) laboratory strains had a six-(ARVAC, Fort Dodge Laboratories, IA) was derived from
the original Bucyrus isolate of EAV (22–25). Each virus contiguous-nucleotide deletion (11283–11288) and,
therefore, the ORF5 sequence of these 2 laboratorywas propagated in confluent monolayers of RK-13 cells
to generate the working virus stocks (26). Three different strains was shorter than the published sequence of EA-
VUtr. Most of the nucleotide differences in ORF5 werelaboratory strains of the original prototype Bucyrus iso-
late of EAV also were compared in this study. The Califor- clustered within nucleotides 11281 to 11788, whereas
nucleotides 11129–11280 and 11789–11896 were mod-nia Veterinary Diagnostic Laboratory System (CVDLS)
strain of EAV (EAVCVDLS; generously provided by Dr. A. erately conserved among all the viruses. The number of
nucleotide differences in ORF5 of each virus varied fromCastro, CVDLS, Davis, CA) was originally obtained from
the National Veterinary Services Laboratory, Ames, IA. 3 to 94 (87.8–99.6% homology), compared to the pub-
lished sequence (EAVUtr; 4). The vaccine virus had 14Our prototype virus (EAVUCD) was derived from the
EAVCVDLS strain and was sequentially plaque-picked nucleotide differences (98.2% homology) from the pub-
lished sequence (EAVUtr) and differed from each of thethree times from agar-overlaid Vero cells prior to propa-
gation in RK-13 cells. The 3rd laboratory strain of the field isolates at 8–104 nucleotides. Although the vaccine
virus had been extensively passaged in cell culture (Ta-Bucyrus virus was obtained from the American Type Cul-
ture Collection (ATCC; Rockville, MD) and subsequently ble 1), its ORF5 sequence was very similar to the pub-
lished sequence and to that of the PLD76 field isolatewas passaged once each in RK-13 and BHK-21 cells
(ATCC). (98.2 and 99% homology). The vaccine virus only differed
at 13–26 nucleotides from the other 3 laboratory strainsTotal RNA was extracted from virus-infected RK-13
cells, as previously described (7). The published se- of the Bucyrus virus. The field isolates differed from each
other by between 2 and 110 nucleotides (85.7–99.7%quence of another laboratory strain of the original Bu-
cyrus virus (EAVUtr; 4) was used to design synthetic oli- homology). The ORF5 nucleotide sequence of the virulent
Bucyrus strain (VBS53) was identical to that of the ATCCgodeoxynucleotide primers (National Biosciences, MN)
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TABLE 1
Origin and Passage History of EAV Isolates
Virus isolate Year of isolation Location/country of origin Breed Passage history
VBS53 1953 Bucyrus, Ohio, U.S.A. STB Eq 15
KY63 1963 Kentucky, U.S.A. ASB HK 3, ED 1, RK 1
SWZ64 1964 Bibuna, Switzerlanda Mixed HK 5, RK 3, ED 1, RK 1
AUT68 1968 Vienna, Austriab Warmblood HK 5, RK 2
PA76 1976 Pennsylvania, U.S.A. STB RK 2
PLD76 1976/1977 Wroclaw, Polandc TB RK 2
KY77 1977 Kentucky, U.S.A. STB RK 2
KY84 1984 Kentucky, U.S.A. TB RK 2
CAN86 1986 Alberta, Canada TB RK 3
AZ87 1987 Arizona, U.S.A. AB RK 2
NE88 1988 Nebraska, U.S.A. AB RK 2
MT89 1989 Montana, U.S.A. AB RK 2
NE89 1989 Nebraska, U.S.A. AB RK 3
ITA92 1992 Italy d Maremmana RK 2
IL93TB 1993 Illinois, U.S.A. TB RK 2
KY93 1993 Kentucky, U.S.A. TB RK 3
MI93 1993 Michigan, U.S.A. STB RK 2
IL93AB 1993 Illinois, U.S.A. AB RK 3
ARVAC N/A Ford Dodge Laboratories, U.S.A. STB HK 131, RK 111, ED 24
ATCC N/A American Type Culture Collection, U.S.A. STB Eq 15, LLC-MK 1, RK 1, BHK 1
EAVCVDLS N/A California Vet. Diag. Lab. Sys., U.S.A. N/A RK high passage
EAVUCD N/A University of California, Davis, U.S.A. N/A Vero 3, RK 2
Note. Cells: HK, primary horse kidney; ED, equine dermis; RK, rabbit kidney 13; LLC-MK, rhesus monkey kidney cell line 2; BHK, baby hamster
kidney 21; and Vero, African green monkey kidney cells. Passage history: each cell type is followed by the number of passages on that particular
cell type (e.g., RK 3, passaged 3 times in rabbit kidney 13 cells; Eq 15, 15 serial passages in horses). Horse breed: TB, thoroughbred; STB,
standardbred; AB, Arabian; ASB, American saddlebred.
a and b Dr. Franz Bu¨rki, Virology Institute, Veterinary Medical School, Vienna.
c Dr. Berndt Klingeborn, The National Veterinary Institute, Uppsala, Sweden.
d Dr. G. L. Autorino, Instituo Zooproflattico Sperimentale delle Regioni Lazio eTuscane, Rome.
strain and differed at only 3 nucleotides from the pub- a particular geographic area were not consistently pres-
ent in the later isolates from the same area and somelished sequence (99.6% homology).
Some nucleotide differences were unique to a single differences were unique to individual viruses regardless
of the year of isolation (e.g., European isolates AUT68virus (e.g., nucleotides 11142 in ITA92, 11159 in NE88,
11234 in PA76, and 11290 in KY63), whereas others were and ITA92 [nucleotides at positions 11152, 11154, 11281,
11284, 11306, 11371, 11378, 11395, and 11396] andcommon to most of the field isolates (e.g., positions
11369, 11393, 11397, 11476, 11483, 11680, and 11719). United States’ isolates NE88, NE89, IL93TB, and IL93AB
[nucleotides at positions 11133, 11134, 11136, 11159,Some nucleotide differences were common to most of
the isolates from a particular geographical area (North 11309, 11311, 11328, and 11648 of the Nebraska isolates
and 11531 and 11562 of the Illinois isolates]). These dataAmerica or Europe) or to all isolates from a particular
year (e.g., position 11136 in KY63, KY77, KY84, KY93, suggest that nucleotide differences are not necessarily
cumulative, as there may be reversal of individual nucleo-IL93TB, IL93AB, MI93, and NE89), whereas others were
unique to individual isolates from one geographical area tide changes along with new changes at different sites
over time. The data also show genetic heterogeneityor isolates of a particular year (e.g., positions 11765 in
KY77, 11531 and 11562 in IL93AB, 11273 in IL93TB, and among EAV field isolates collected from the same geo-
graphic region over several years (e.g., European iso-11234, 11327, 11341, 11449, and 11491 in PA76). Some
differences were present in isolates from a particular lates SWZ64, AUT68, and ITA92 and some of the United
States isolates). The different nucleotide changes in indi-geographic area or particular year, while other field iso-
lates from the same area or year had the same nucleotide vidual viruses from North America and Europe indicate
that EAV may have evolved via different lineages generat-as the published sequence (EAVUtr). Nucleotide differ-
ences common to most of the field isolates suggest an ing new consensus sequences unique to each virus.
The 18 field isolates, 4 different laboratory strains ofancestor-dependent relationship but other nucleotide dif-
ferences clearly are not consistent with this hypothesis. the original prototype Bucyrus strain of EAV (ATCC,
EAVCVDLS, EAVUCD, and EAVUtr), and the ARVAC vac-Specifically, nucleotide differences in early isolates from
/ m4655$7653 11-21-95 18:40:52 vira AP-Virology
693SHORT COMMUNICATION
FIG. 1. Phylogenetic tree of the 4 laboratory strains of EAV, the ARVAC vaccine virus, and 18 field isolates of EAV from North America and Europe.
The ORF5 of lactate dehydrogenase elevating virus (LDV) was used as an outgroup (29). Horizontal branchlengths reflect genetic distances that
are proportional to the scale bar.
cine virus were clustered into two distinct monophyletic the ARVAC vaccine virus, and all the laboratory strains
of EAV. The European isolate PLD76 was more closelylineages (clades; Fig. 1). The first, larger clade (NA1
group) includes all the North American isolates except related to the laboratory strains, and especially to the
ARVAC vaccine (99.0% homology), than to the otherKY63 and AZ87, 1 of the European isolates (PLD76), the
vaccine virus, and all laboratory strains of EAV. This European and North American viruses. Bootstrap analy-
sis placed a very high confidence value (99%) at thelargest clade in turn splits into two distinct monophyletic
lineages with 9 viruses in each lineage (Fig. 1). Bootstrap branching of ARVAC and PLD76.
The second, smaller clade includes two United Statesanalysis placed a high confidence value of 92% at the
branching node of these two monophyletic groups. With isolates (KY63 and AZ87) and three European isolates
(SWZ64, AUT68, and ITA92; Fig. 1). The genetic distancethe notable exception of AZ87, all the United States’ iso-
lates after 1976 were clustered together, indicating that matrix analyses indicate that these five viruses are more
distantly related to PLD76 (Polish isolate), the laboratorythese viruses are closely related. These viruses were
isolated in different regions within the United States (cen- strains, and the other North American isolates (data not
shown). However, the confidence value by bootstraptral and western United States) over a period of 17 years
but differ from one another at only 2–57 nucleotides analysis was low, indicating that the order of descent of
these five viruses was not fully resolved by this analysis(92.6–99.7% homology), whereas they differ from all other
North American and European viruses at 37–110 nucleo- (data not shown). The second, smaller clade, split into
two distinct monophyletic lineages with SWZ64 as thetides (85.7–95.2% homology). Predictably, all 1993 iso-
lates (IL93TB, IL93AB, KY93, and MI93) are highly related sole member of one lineage (E1 group). The ORF5 se-
quence of two European isolates (AUT68 and ITA92) dif-as all were derived, directly or indirectly, from the Chi-
cago clinic that was the initial source of the outbreak of fered from the North American isolate AZ87 by only 28–
45 nucleotides (94.1–96.4%), thus these three virusesviral arteritis which occurred in the midwestern United
States during the summer of 1993. The second lineage are more closely related to each other than they are to the
other North American isolates and two other Europeancontained the 2 United States viruses (VBS53 and PA76),
the Canadian virus (CAN86), the Polish virus (PLD76), isolates (SWZ64 and PLD76). Therefore, it is appropriate
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to separate SWZ64 into an independent group within other laboratory strains of the Bucyrus virus (253 instead
of 255 amino acids). The number of amino acid substitu-the clade. The KY63, AUT68, AZ87, and ITA92 viruses
clustered into one lineage which in turn bifurcated into tions in the GL protein of these viruses, compared to the
published sequence (4), varied from 3 (98.8% homology)two sister lineages. The KY63 isolate formed an indepen-
dent group (NA2 group), whereas AUT68, ITA92, and AZ87 in VBS53 and ATCC to 24 for AZ87 (90.6% homology).
The field isolates differed from each other by between 1were clustered into one group (E2 group). The KY63 virus
differed from all other isolates by 87–110 nucleotides and 26 amino acids (89.8–99.6% homology). The number
of amino acid substitutions per virus ranged from 4 to(85.7–88.7% homology) and thus it differs from all the
North American and European viruses. In addition to this, 30 among the EAV field isolates and the vaccine virus.
Many nucleotide changes in ORF5 of the EAV field iso-distance matrix analyses indicate that the KY63 isolate
is more distantly related to AUT68, ITA92, and AZ87 and, lates were silent and, therefore, there were extensive
regions of amino acid homology in the GL protein of EAVtherefore, it is appropriate to group it in an independent
lineage (data not shown). The sharing of a common an- field isolates (Fig. 2). There were four distinct conserved
regions (C1 [aa 19–60], C2 [aa 122–140], C3 [aa 179–cestor by AUT68, AZ87, and ITA92 is supported by the
high bootstrap confidence value of 97% at the branching 201], and C4 [aa 223–255]) in the GL protein of the vi-
ruses. The only exceptions were IL93TB, which had anode. The grouping of AZ87 with the European viruses
in group E2 (AUT68 and ITA92) suggests the transfer of single amino acid substitution at amino acid 49 (aspartic
acid to asparagine) in the C1 conserved region (Fig. 2),a European virus to the United States, which is consistent
with the fact that AZ87 was isolated from the semen of and EAVUCD and EAVCVDLS, which had identical con-
servative amino acid changes at positions 44 (aspara-a stallion imported into the United States from Poland in
late 1986. Several mares bred to this stallion in Arizona gine to serine) and 54 (leucine to methionine) in the C1
conserved region. Two amino acids also were deleteddeveloped viral arteritis. Similarly, the Polish isolate
(PLD76) is remarkably similar to the original Bucyrus at positions 52 and 53 of these 2 viruses (Fig. 2).
Amino acid substitutions were clustered into four dis-strain of EAV that was isolated in the United States in
1953 and even more so to the vaccine virus. tinct regions of the GL protein of the different viruses (S
[1–18], V1 [61–121], V2 [141–178], and V3 [202–222]; Fig.Previous comparisons of the M and N protein genes
(encoded by ORF6 and 7) of EAV isolates suggested the 2). The S and V1 regions were located in the amino-
terminal half of the GL protein, and the V1 region consti-existence of three EAV variants represented by isolates
from the United States (Bucyrus), Austria (Vienna), and tutes approximately one-quarter of the entire GL protein
(61 amino acids). Significantly, most of the amino acidSwitzerland (Bibuna; 17, 18), which is similar to our find-
ings with the GL protein gene (ORF5). Chirnside et al. substitutions in the V1 region were nonconservative.
The S region includes amino acids 1 to 18 (Fig. 2). Theshowed evidence of RNA recombination between EAV
isolates (17); however, there was no evidence of RNA first 18 amino acids in the amino terminus of the GL
protein are hydrophobic and are assumed to function asrecombination in ORF5 of EAV isolates included in our
study. Furthermore, phylogenetic analysis of EAV field a signal sequence which may be cleaved from the mature
protein (5, 34). These initial 18 amino acids were highlyisolates indicates that although viruses from one area
may cluster in the same phylogenetic group, they do conserved in all the laboratory strains of EAV, the vaccine
virus, and some field isolates (VBS53, MT89, PA76, andnot consistently share an immediate common ancestor.
Together the data suggest that nucleotide substitutions PLD76; Fig. 2). In contrast, some of the field isolates had
common or unique amino acid substitutions in the regionin EAV do not necessarily follow a linear pattern of accu-
mulation over time, which further suggests that EAV does of amino acids 2 to 14 (e.g., substitution of valine to
alanine at position 14, substitution of threonine for isoleu-not consistently evolve via an ancestor-dependent path-
way but may behave as a ‘‘quasispecies’’ in nature, as cine at position 5, and substitution of serine for leucine
at position 10; Fig. 2). However, the amino acid substitu-has previously been shown for several other RNA viruses
(12, 13, 31–33). tions that occurred in this region are typical of those
found in other signal sequences and it is likely, therefore,Nucleotide sequences of all 18 field isolates of EAV,
the ARVAC vaccine, and the laboratory strains were that the function of the signal sequence is unaffected by
these substitutions.translated into amino acid sequences, and predictions
of hydrophobicity and secondary structure were made The V1 region includes amino acids 61 to 121 (Fig. 2).
Most of the amino acid substitutions in this region werewith a Macintosh IIsi computer using the HIBIO MacD-
NASIS Pro Version 3.0 software program (Hitachi). The shared by the field isolates (e.g., positions 79, 85, 89, and
90). Some of the substitutions, however, were unique todeduced amino acid sequences of the GL protein of these
viruses are shown in Fig. 2. Due to the deletion of six a particular field isolate (e.g., AUT68, position 61; NE88,
positions 67 and 85; ITA92, position 79; and KY63, positioncontiguous nucleotides, the GL protein of 2 laboratory
strains of EAV (EAVUCD and EAVCVDLS) was 2 amino 88). Some amino acid substitutions were unique to the
laboratory strains of EAV (e.g., EAVUCD and EAVCVDLS,acids shorter than that of all other viruses including 2
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FIG. 2. Aligned deduced amino acid sequence of the GL proteins of the prototype (EAVUtr) and 3 other laboratory strains, the ARVAC vaccine
virus, and 18 field isolates of EAV. Dots indicate the same amino acid as in the top aligned sequence. The putative signal sequence (S), the
conserved regions (C1 , C2 , C3 , and C4), and the variable regions (V1 , V2 , and V3) are indicated above the sequences. The two predicted glycosylation
sites are indicated by bold letters. Deleted amino acids are indicated by an ‘‘X’’.
positions 83 and 87). In contrast some of the substitutions epitopes on the GL protein (7). Recently, Glaser et al.,
also demonstrated that amino acids 96, 99, 100, and 113were shared by the laboratory strains and the field isolates
(e.g., positions 73, 82, and 84). Except for AZ87, ITA92, are critical for virus neutralization (10). Significantly, these
sites all fall within the V1 variable region (amino acidsand AUT68, the aspartic acid to valine substitution at posi-
tion 101 was common to all the field isolates, the vaccine 61 to 121) that we identified among the field isolates.
Interestingly, this V1 region includes the second half ofvirus, and the laboratory strains of EAV. The PLD76 and
ARVAC vaccine virus had four identical amino acid substi- the predicted amino-terminal hydrophilic ectodomain of
the GL protein. Given that the V1 region of the GL proteintutions at positions 69, 100, 101, and 104. All the amino
acid substitutions in the V1 region were clustered into is important to virus neutralization, we compared the hy-
drophobicity (Fig. 3) and secondary structure of this re-three distinct areas that included amino acids 61–90,
100–106, and 119–121, and these three areas were sepa- gion among the viruses (35, 36). In some viruses the
hydrophobicity was changed only in the region of aminorated by two highly conserved regions (positions 91–99
and 107–118; Fig. 2). acids 61–90 or 100–106 (e.g., aa 61–90: IL93TB, IL93AB,
MI93, KY84, PA76, NE88, NE89, MT89, KY77, and KY93The hydrophobicity profile of the GL protein of EAV has
been previously reported and amino acid residues 19 [representative example Fig. 3b]; aa 100–106: PLD76 and
ARVAC [representative example Fig. 3c]), whereas in oth-through 116 are predicted to constitute the hydrophilic
ectodomain (5, 34). Amino acids 54 through 99 in the ers either two or three areas within the V1 region had
hydrophobicity changes (e.g., aa 61–90 and 119–121:predicted hydrophilic ectodomain of the GL protein are
proposed to be responsible for virus neutralization (9, CAN86, AUT68, and SWZ64 [representative example Fig.
3d]; aa 61–90, 100–106, and 114–121: KY63, AZ87, and34), although no amino acid substitutions were found
between amino acids 54 and 60 in this study. In a previ- ITA92 [representative example Fig. 3e]). Amino acid sub-
stitutions generally made the GL protein markedly moreous study, we have shown that amino acids 99 to 104 are
critical to expression of three interactive neutralization hydrophobic in, or adjacent to, the region of the substitu-
/ m4655$7653 11-21-95 18:40:52 vira AP-Virology
696 SHORT COMMUNICATION
FIG. 3. Comparison of hydropathy profiles of the ORF5 translation products of the prototype (EAVUtr) laboratory strain of EAV, the ARVAC vaccine
virus, and selected EAV field isolates (representative examples given in the text), as determined by the method of Kyte and Doolittle (35) with a
window of 3 amino acid residues. Only the hydropathy profiles of 61 amino acids within the GL protein are depicted (aa 61–121), as this includes
the entire V1 region of the protein. Peaks extending upward indicate hydrophobic domains, and those pointing downward correspond to hydrophilic
regions. The hydropathy changes are indicated by arrows. (a) EAVUtr, (b) MT89, (c) ARVAC vaccine, (d) CAN86, and (e) KY63.
tion. In IL93TB, however, substitutions in the area of secondary structure could have a significant effect on
the neutralization determinants of EAV.amino acids 61–90 made the region more hydrophilic.
Amino acid substitutions also significantly altered the The aspartic acid to asparagine substitution at position
81 created a new, potential second glycosylation site inpredicted secondary structure of the GL protein in some
viruses (data not shown; 36). For instance, the seven the GL protein of the ATCC virus and 16 of the field
isolates (Fig. 2). This second potential glycosylation siteamino acid substitutions in the 61–90 and 100–106 re-
gions of the AZ87 virus result in an increased area of within the V1 region of the GL protein of ATCC and some
of the field isolates may have a significant effect on thepredicted sheet structure rather than helical structure.
The proline and lysine substitutions at positions 69 and neutralization determinants of these viruses. Together
these data suggest that amino acid changes within the72 and the glycine substitutions at positions 100 and
104 of the vaccine virus increase the coiled and sheet V1 region of the GL protein could influence the antigenicity
of the envelope of EAV and perhaps lead to the emer-probability in these regions. The hydrophobicity profiles
and secondary structure of the ATCC and VBS53 viruses gence of strains with different neutralization phenotypes.
This is consistent with recent studies that have shownwere identical to those of EAVUtr. In summary, significant
changes in predicted hydrophobicity and secondary some differences in neutralization of field isolates of EAV
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